| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-11-04 | linaclotide | chronic idiopathic constipation | 3 | Ironwood Pharmaceuticals (USA - MA) | Digestive diseases - Gastrointestinal diseases - Inflammatory diseases |
| 2014-11-04 | trebananib | recurrent platinum-resistant ovarian cancer |
3 | Amgen (USA - CA) | Cancer - Oncology |
| 2014-11-03 | MGN1331 - DNA vaccine against leishmaniasis | leishmaniasis |
preclinical | Mologen (Germany) and the LEISHDNAVAX consortium | Infectious diseases |
| 2014-11-03 | SAGE-547 | super-refractory status epilepticus (SRSE) | 1-2 | Sage Therapeutics (USA - MA) | CNS diseases - Neurological diseases |
| 2014-11-03 | Abilify Maintena® (aripiprazole extended-release injectable suspension, for intramuscular use) | schizophrenia |
Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | Mental diseases | |
| 2014-11-03 | lorcaserin HCl | smoking cessation |
2 | Eisai (Japan) Arena Pharmaceuticals (USA - CA) | |
| 2014-11-03 | IPH4102 | cutaneous T-cell lymphomas, and especially their aggressive forms: Sezary Syndrome and Transformed Mycosis Fungoides | preclinical | Innate Pharma (France) | Cancer - Oncology |
| 2014-11-03 | imetelstat | myelofibrosis | 2 | Geron (USA - CA) | Rare diseases |
| 2014-11-03 | ARGX-110 | relapsed or refractory Waldenström’s macroglobulinemia |
1b-2 | Argen-X (Belgium) | Cancer - Oncology - Rare diseases |
| 2014-11-03 | EBI-005 | dry eye disease |
3 | Eleven Biotherapeutics (USA - MA) | Ophtalmological diseases |
| 2014-10-31 | SonR cardiac resynchronization therapy | severe heart failure |
Sorin (Italy) | Cardiovascular diseases | |
| 2014-10-30 | AMAP102 | inflammatory pain in osteoarthritis |
2a | Anamar (Sweden) | Rheumatic diseases - CNS diseases |
| 2014-10-30 | anamorelin | anorexia/cachexia in patients with advanced non-small cell lung cancer (NSCLC) |
3 | Helsinn (Switzerland) | Cancer - Oncology |
| 2014-10-30 | Xtandi® (enzalutamide) | high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy | 3 | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology |
| 2014-10-29 | Belviq® (lorcaserin HCl) and phentermine HCl | chronic weight management |
Eisai (Japan) Arena Pharmaceuticals (USA - CA) | Metabolic diseases | |
| 2014-10-29 | ME-344 in combination with topotecan | patients with small cell lung or ovarian cancer who failed initial therapy. |
1b | Mei Pharma (USA - CA) | Cancer - Oncology |
| 2014-10-29 | LT-02 | mild-moderate ulcerative colitis |
3 | Lipid Therapeutics (Germany) Dr. Falk Pharma (Germany) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2014-10-28 | antibody drug conjugate (ADC) technology | Innate Pharma (France) | Technology - Services | ||
| 2014-10-28 | APG101 (asunercept) | glioblastoma | 2 | Apogenix (Germany) | Cancer - Oncology |
| 2014-10-28 | MBC-11 | cancer-induced bone disease |
1 | Osteros Biomedica (Russia) | Cancer - Oncology - Bone diseases |
